Reynders McVeigh Capital Management LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 26.9% in the 1st quarter, Holdings Channel reports. The firm owned 13,734 shares of the biopharmaceutical company’s stock after selling 5,046 shares during the quarter. Reynders McVeigh Capital Management LLC’s holdings in Gilead Sciences were worth $893,000 at the end of the most recent quarter.
Other large investors have also added to or reduced their stakes in the company. Athena Capital Advisors LLC bought a new position in Gilead Sciences during the 4th quarter valued at $27,000. Capital Financial Planning LLC bought a new position in Gilead Sciences during the 4th quarter valued at $27,000. Creative Financial Designs Inc. ADV boosted its stake in Gilead Sciences by 55.9% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 165 shares in the last quarter. Claybrook Capital LLC bought a new position in Gilead Sciences during the 4th quarter valued at $32,000. Finally, Trustcore Financial Services LLC bought a new position in Gilead Sciences during the 1st quarter valued at $34,000. Institutional investors and hedge funds own 78.78% of the company’s stock.
Shares of GILD traded up $1.20 during mid-day trading on Wednesday, reaching $67.30. The company’s stock had a trading volume of 137,641 shares, compared to its average volume of 7,131,615. The firm has a market capitalization of $83.31 billion, a P/E ratio of 10.91, a PEG ratio of 0.80 and a beta of 1.09. Gilead Sciences, Inc. has a 1 year low of $60.32 and a 1 year high of $79.61. The company has a quick ratio of 3.53, a current ratio of 3.62 and a debt-to-equity ratio of 1.09.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.53 by $0.23. The company had revenue of $5.28 billion during the quarter, compared to analyst estimates of $5.29 billion. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.48 earnings per share. On average, analysts expect that Gilead Sciences, Inc. will post 6.6 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be issued a $0.63 dividend. The ex-dividend date is Thursday, June 13th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.74%. Gilead Sciences’s payout ratio is currently 40.98%.
In related news, Director Richard James Whitley sold 9,534 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $65.48, for a total transaction of $624,286.32. Following the completion of the sale, the director now directly owns 34,669 shares in the company, valued at $2,270,126.12. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director John Francis Cogan sold 2,868 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $64.89, for a total value of $186,104.52. Following the sale, the director now owns 57,728 shares of the company’s stock, valued at $3,745,969.92. The disclosure for this sale can be found here. Insiders sold 28,602 shares of company stock valued at $1,863,445 in the last 90 days. Corporate insiders own 0.20% of the company’s stock.
A number of equities analysts have issued reports on GILD shares. Citigroup lowered Gilead Sciences from a “buy” rating to a “neutral” rating and decreased their price target for the company from $100.00 to $75.00 in a research note on Tuesday, February 12th. Raymond James decreased their price target on Gilead Sciences from $90.00 to $85.00 and set a “strong-buy” rating for the company in a research note on Tuesday, February 12th. ValuEngine lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, February 13th. Mizuho reaffirmed a “buy” rating and set a $88.00 price target on shares of Gilead Sciences in a research note on Tuesday, February 26th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Thursday, March 7th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and an average target price of $79.54.
ILLEGAL ACTIVITY WARNING: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.dispatchtribunal.com/2019/06/12/gilead-sciences-inc-nasdaqgild-holdings-reduced-by-reynders-mcveigh-capital-management-llc.html.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Further Reading: What are different types of coverage ratios?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.